Status:
UNKNOWN
Safety and Efficacy of Extracorporeal Cytokine Hemoadsorption in Septic Shock in Critically Ill Cirrhotics
Lead Sponsor:
Institute of Liver and Biliary Sciences, India
Conditions:
Septic Shock
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Patients with septic shock would be screened. Following this, patients meeting the inclusion and exclusion criteria will be screened and randomized to the two treatment groups. Standard criteria will ...
Eligibility Criteria
Inclusion
- \- Critically ill cirrhotics with early onset septic shock (\<24 hours) with norepinephrine of more than 10 ug/min and lactate \>4 mmol/L.
Exclusion
- Patients with age less than 18 years
- Severe known cardiopulmonary disease (structural or valvular heart disease, coronary artery disease, COPD)
- Severe coagulopathy platelets \<20,000 and INR \>5
- Active Bleed (Mucosal or variceal)
- Pregnancy
- Chronic kidney disease
- Extremely moribund patients with an expected life expectancy of less than 24 hours
- Failure to give informed consent from family members.
- Hemodynamic instability requiring very high dose of vasopressors, late presentation or spontaneous reversal of shock
- Patient enrolled in other clinical trials
Key Trial Info
Start Date :
March 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2019
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03866083
Start Date
March 1 2019
End Date
June 30 2019
Last Update
May 1 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Liver & Biliary Sciences
New Delhi, National Capital Territory of Delhi, India, 110070